CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Iambic CEO on taking an AI drug company public

IPO/OfferingPositive
AI Analysis

Summary

Iambic Therapeutics, an AI-focused drug developer, recently completed a $150 million IPO. CEO Tom Miller discussed the roadshow process and how he sees AI's role in drug development evolving.

Outcome Details

Iambic completed a $150 million IPO; CEO Tom Miller discussed the roadshow process and AI's evolving role in drug development.

Importance:5/10
Sentiment:
0.40
IPOAI drug discoveryinterviewroadshow
Related Companies

Read the original article

Published by BioPharma Dive on October 16, 2026 4:10 PM

Read Original